PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 176 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $76,710 | -20.9% | 7,892 | -16.5% | 0.00% | 0.0% |
| Q4 2020 | $97,008 | +1.7% | 9,455 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $95,401 | -5.9% | 9,455 | -2.8% | 0.00% | 0.0% |
| Q2 2020 | $101,421 | +23.6% | 9,724 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $82,071 | -2.7% | 9,724 | +0.9% | 0.00% | +100.0% |
| Q4 2019 | $84,341 | -26.2% | 9,639 | -9.2% | 0.00% | -50.0% |
| Q3 2019 | $114,270 | -3.4% | 10,615 | +14.0% | 0.00% | 0.0% |
| Q2 2019 | $118,330 | -67.2% | 9,310 | 0.0% | 0.00% | -71.4% |
| Q1 2019 | $361,135 | +83.0% | 9,310 | -4.0% | 0.01% | +75.0% |
| Q4 2018 | $197,354 | -53.8% | 9,698 | +4.0% | 0.00% | -50.0% |
| Q3 2018 | $427,505 | -99.9% | 9,324 | 0.0% | 0.01% | -11.1% |
| Q2 2018 | $551,514,000 | -13.1% | 9,324 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $634,498,000 | +69778.6% | 9,324 | +1.5% | 0.01% | -25.0% |
| Q4 2017 | $908,000 | -61.4% | 9,186 | -53.2% | 0.01% | -20.0% |
| Q3 2017 | $2,350,000 | +35.9% | 19,626 | -0.8% | 0.02% | +25.0% |
| Q2 2017 | $1,729,000 | +130.8% | 19,785 | -1.8% | 0.01% | +140.0% |
| Q1 2017 | $749,000 | +21.2% | 20,142 | 0.0% | 0.01% | +25.0% |
| Q4 2016 | $618,000 | -48.5% | 20,142 | +12.6% | 0.00% | -55.6% |
| Q3 2016 | $1,200,000 | +119.4% | 17,895 | -2.6% | 0.01% | +125.0% |
| Q2 2016 | $547,000 | +894.5% | 18,371 | +879.8% | 0.00% | – |
| Q1 2016 | $55,000 | -62.6% | 1,875 | 0.0% | 0.00% | -100.0% |
| Q4 2015 | $147,000 | +6.5% | 1,875 | +2.7% | 0.00% | 0.0% |
| Q3 2015 | $138,000 | -35.2% | 1,825 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $213,000 | -95.2% | 1,825 | -90.3% | 0.00% | -97.0% |
| Q1 2015 | $4,433,000 | +31.5% | 18,775 | +5.4% | 0.03% | +43.5% |
| Q4 2014 | $3,370,000 | -20.7% | 17,805 | 0.0% | 0.02% | -25.8% |
| Q3 2014 | $4,248,000 | +246.8% | 17,805 | -4.0% | 0.03% | +244.4% |
| Q2 2014 | $1,225,000 | -36.6% | 18,555 | 0.0% | 0.01% | -30.8% |
| Q1 2014 | $1,932,000 | +4.7% | 18,555 | +4.1% | 0.01% | 0.0% |
| Q4 2013 | $1,846,000 | +104.7% | 17,826 | +6.1% | 0.01% | +85.7% |
| Q3 2013 | $902,000 | +5.5% | 16,807 | -12.7% | 0.01% | 0.0% |
| Q2 2013 | $855,000 | – | 19,263 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Avalon Global Asset Management LLC | 30,000 | $3,503,000 | 2.29% |
| WEATHERBIE CAPITAL, LLC | 141,123 | $16,476,000 | 1.67% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $663,918,000 | 1.66% |
| BB BIOTECH AG | 521,991 | $60,942,000 | 1.65% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 317,032 | $37,013,000 | 1.21% |
| Orbimed Advisors | 940,800 | $109,838,000 | 0.81% |
| Perceptive Advisors | 100,000 | $11,675,000 | 0.70% |
| Ghost Tree Capital, LLC | 17,500 | $2,043,000 | 0.66% |
| CAPITAL INTERNATIONAL LTD /CA/ | 90,935 | $10,617,000 | 0.63% |
| Fernwood Investment Management, LLC | 6,800 | $794,000 | 0.62% |